share_log

中源协和(600645.SH):存储业务包括新生儿脐带血造血干细胞等

Zhongyuan Kyowa (600645.SH): Storage business includes neonatal cord blood hematopoietic stem cells, etc.

Gelonghui Finance ·  May 14 04:04

Gelonghui, May 14, 丨 Zhongyuan Xiehe (600645.SH) said on the investor interactive platform that the company's storage business includes neonatal umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental subpluripotent stem cells, and adult immune cells, adipose mesenchymal stem cells, and dental pulp mesenchymal stem cells. In terms of cell therapy research and development, the company's current indications for VUM02 injections derived from umbilical cord mesenchymal stem cells are: decompensated liver cirrhosis, idiopathic pulmonary fibrosis, slow acute (subacute) liver failure, acute respiratory distress syndrome, grade II to IV acute graft-versus-host disease (aGVHD) where hormone therapy fails, and the clinical classification of treatment is heavy/critical novel coronavirus infection. The “human endodontic mesenchymal stem cell injection” jointly declared by Beijing Sanli Company, which is a shareholder, and Capital Medical University is used to treat chronic periodontitis. In addition, the company's current stem cell filing projects mainly include the “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for Neuropathic Pain” project, the “Randomized Double-blind Controlled Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for Treating Hepatitis B Hepatic Cirrhosis (Compensation Period)”, the “Clinical Study on Liver Regeneration Effects of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients with Chronic Kidney Disease (CKD3, Stage 4)”, “Clinical Study on Liver Regeneration Effects of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Chronic Kidney Disease Patients (CKD3, 4) “Clinical Research” project, “Umbilical cord mesenchymal stem cell therapy” The “Clinical Study on Refractory Diabetic Peripheral Neuropathy” and the “Randomized, Double-blind, Placebo-Controlled, Multi-Center Clinical Study on the Efficacy and Safety of Human Umbilical Source Mesenchymal Stem Cells Combined with Standard Therapy for Patients with Decompensated Liver Cirrhosis”, etc.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment